NCT07524374尚未招募2 期
The Efficacy, Safety and Feasibility of SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of Esophageal Squamous Cell Carcinoma After Immunotherapy
Zhigang Li1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2026年3月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
This study is a single-arm, exploratory clinical trial aimed at evaluating the efficacy and safety of SHR-1701 in combination with liposomal irinotecan (II) in patients with esophageal squamous cell carcinoma who have received prior immunotherapy. Eligible patients with esophageal cancer will be treated with SHR-1701 in combination with liposomal irinotecan (II).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent, voluntarily participating in this study;
- •Histopathologically or cytologically confirmed esophageal squamous cell carcinoma;
- •Prior treatment with immunotherapy;
- •At least one measurable lesion as assessed by RECIST version 1.1;
- •Age ≥ 18 years, male or female;
- •ECOG performance status of 0 or 1;
- •Life expectancy > 3 months;
- •Adequate organ function:
- •Hematology: Neutrophils ≥ 1.5 × 10^9/L, Hemoglobin ≥ 9 g/dL, Platelets ≥ 100 × 10^9/L.
- •Hepatic function: Bilirubin ≤ 1.5 × the upper limit of normal (ULN) (patients with known Gilbert's disease and serum bilirubin ≤ 3 × ULN are eligible); AST and ALT ≤ 2.5 × ULN (if liver metastases are present, AST/ALT ≤ 5 × ULN); Alkaline phosphatase ≤ 3 × ULN (if liver or bone metastases are present, ALP ≤ 5 × ULN); Albumin ≥ 3 g/dL.
- •Renal function: Serum creatinine ≤ 1.5 × ULN or estimated glomerular filtration rate by Cockcroft-Gault: Creatinine clearance ≥ 60 mL/min.
- •Coagulation function: International normalized ratio (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
- •Female patients of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose, must not be breastfeeding, and must agree to use effective contraception for 6 months after the last dose; for male patients with a partner of childbearing potential, effective contraception must be used for 3 months after the last dose; sperm donation is not permitted during the study;
- •Patients are well compliant and agree to cooperate with follow-up.
排除标准
- •1. Active or untreated central nervous system (CNS) metastases (e.g., brain or leptomeningeal metastases) as determined by CT or magnetic resonance imaging (MRI) assessment during screening.
- •2. Uncontrolled tumor-related pain.
- •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once a month or more frequently); patients with an indwelling catheter (e.g., PleurX®) are permitted.
- •4. History of a malignancy other than esophageal cancer within 5 years prior to enrollment, except for malignancies with a negligible risk of metastasis or death (e.g., expected 5-year overall survival > 90%) and those that are expected to be cured after treatment.
- •5. History of allergy to monoclonal antibodies, liposomal products, or irinotecan.
- •6. Prior or current receipt of any of the following therapies:
- •Use of immunosuppressive medications or systemic corticosteroid therapy for immunosuppressive purposes (dose > 10 mg/day prednisone or equivalent) within 2 weeks prior to the first dose of study drug; inhaled or topical steroids and adrenal corticosteroid replacement at doses > 10 mg/day prednisone or equivalent are permitted in the absence of active autoimmune disease.
- •Receipt of a live attenuated vaccine within 4 weeks prior to the first dose of study drug.
- •Major surgery or significant traumatic injury within 4 weeks prior to the first dose of study drug.
- •7. Any active autoimmune disease or a history of autoimmune disease.
- •History of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation.
- •9. Presence of poorly controlled cardiac clinical symptoms or diseases.
- •Occurrence of a severe infection within 4 weeks prior to the first dose of study drug.
- •11. Active pulmonary tuberculosis infection as identified by medical history or CT examination.
- •12. Active hepatitis B (HBV DNA ≥ 200 IU/mL or ≥ 1000 copies/mL or ≥ the upper limit of normal), or hepatitis C (positive hepatitis C antibody and HCV RNA above the lower limit of quantification of the assay).
- •13. Pregnant or breastfeeding women.
- •Any other condition judged by the investigator that could lead to forced discontinuation from the study, such as other serious illnesses (including mental illnesses) requiring concomitant treatment, alcoholism, drug abuse, family or social factors, or factors that could affect patient safety or compliance.
研究组 & 干预措施
treatment group
Experimental
SHR-1701+ liposomal irinotecan (II)
干预措施: SHR-1701+ liposomal irinotecan (II) (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: through study completion, an average of 12 weeks
Objective response rate (ORR) defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR).
次要结局
- Disease Control Rate(through study completion, an average of 12 weeks)
- Progression-Free Survival(through study completion, an average of 6 months)
- Oearall survival(through study completion, an average of 12 months)
- Safty(Documented from the time of signing the informed consent form until the end of the safety follow-up period (Day 90 after the last dose) or the initiation of a new anti-cancer therapy, whichever occurs first.)
研究者
Zhigang Li
Principal Investigator
Shanghai Chest Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric CancerNCT07464756The First Affiliated Hospital with Nanjing Medical University80
尚未招募
2 期
SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLCNon-Small Cell Lung CancerNCT07489703Sun Yat-sen University30
尚未招募
不适用
A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung CancerNSCLCNCT07281209Shanghai Chest Hospital40
招募中
2 期
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid TumorsNCT07268040Shanghai Hengrui Pharmaceutical Co., Ltd.400
招募中
2/3 期
Study of HSSH-062501 Tablets in People with Mild to Moderate Chronic Joint PainCTRI/2025/11/097144Himalaya Wellness Company300